scispace - formally typeset
Open AccessJournal ArticleDOI

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Frederick Arce Vargas, +250 more
- 18 Apr 2017 - 
- Vol. 46, Iss: 4, pp 577-586
Reads0
Chats0
TLDR
Use of an anti‐CD25 antibody with enhanced binding to activating Fc&ggr;Rs led to effective depletion of tumor‐infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors.
About
This article is published in Immunity.The article was published on 2017-04-18 and is currently open access. It has received 315 citations till now. The article focuses on the topics: IL-2 receptor & Cancer immunotherapy.

read more

Citations
More filters
Journal ArticleDOI

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells.

TL;DR: It is shown that granzyme A cleaves and activates gasdermin B (GSDMB), a central player in the highly inflammatory cell death process known as pyroptosis, suggesting that this pathway may be a target for future cancer immunotherapies.
Journal ArticleDOI

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

TL;DR: A framework for rationally designing combination therapy strategies based on enhancing major discriminatory functions of the immune system that are corrupted by cancer-namely, antigenicity, adjuvanticity, and homeostatic feedback inhibition is discussed.
Journal ArticleDOI

Genetics and biology of prostate cancer.

TL;DR: Improved disease management will also benefit from artificial intelligence-based expert decision support systems for proper standard of care, prognostic determinant biomarkers to minimize overtreatment of localized disease, and new standards of care accelerated by next-generation adaptive clinical trials.
Journal ArticleDOI

Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer

TL;DR: Findings within the context of concepts in Treg cell development and function derived from preclinical models and insight from approaches targeting Treg cells in clinical settings are discussed.
Journal ArticleDOI

CD4 and CD8 T lymphocyte interplay in controlling tumor growth

TL;DR: An overview of T lymphocyte-driven control of tumor growth is given and the involved tumor-suppressive mechanisms of the immune system, such as senescence surveillance, cancer immunosurveillance, and cancer immunoediting are discussed with respect to recent clinical developments of immunotherapies.
References
More filters
Journal ArticleDOI

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

TL;DR: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone.
Journal ArticleDOI

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

TL;DR: The authors showed that CD4+CD25+ cells contribute to maintaining self-tolerance by downregulating immune response to self and non-self Ags in an Ag-nonspecific manner, presumably at the T cell activation stage.
Journal ArticleDOI

Immune checkpoint blockade: a common denominator approach to cancer therapy

TL;DR: The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands, so drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.
Journal ArticleDOI

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

TL;DR: It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.
Journal ArticleDOI

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

TL;DR: The authors’ full names, academic de‐ grees, and affiliations are listed in the Ap‐ pendix.
Related Papers (5)